|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2002-4-19
|
|
pubmed:abstractText |
Improvements in the identification of tumor-associated antigens and in our understanding of the mechanisms regulating antitumor immune responses have revived interest in the use of therapeutic cancer vaccination. Due to their unique characteristics, hematologic malignancies represent an ideal target for vaccine-based therapeutic interventions.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1073-2748
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
9
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
138-51
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11965234-Animals,
pubmed-meshheading:11965234-Antigens, Neoplasm,
pubmed-meshheading:11965234-Bone Marrow Transplantation,
pubmed-meshheading:11965234-Cancer Vaccines,
pubmed-meshheading:11965234-Clinical Trials as Topic,
pubmed-meshheading:11965234-Epitopes,
pubmed-meshheading:11965234-Forecasting,
pubmed-meshheading:11965234-Hematologic Neoplasms,
pubmed-meshheading:11965234-Humans,
pubmed-meshheading:11965234-Immune System,
pubmed-meshheading:11965234-Leukemia, Myeloid,
pubmed-meshheading:11965234-Treatment Outcome
|
|
pubmed:articleTitle |
Cancer vaccines for hematologic malignancies.
|
|
pubmed:affiliation |
Department of Oncology at the Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA. iborrell@jhmi.edu
|
|
pubmed:publicationType |
Journal Article,
Review,
Research Support, Non-U.S. Gov't
|
